We are thrilled to announce that Qinecsa will be sponsoring the World Drug Safety Congress America 2024! THE LARGEST DRUG SAFETY EVENT IN THE WORLD
Pharmacovigilance is a critical component of the medicinal product lifecycle, focusing on ensuring the safety and efficacy of medicinal products from pre-clinical development through post-marketing
We are thrilled to announce that Qinecsa will be sponsoring the World Drug Safety Congress Europe 2024, marking our third year! EUROPE’S MOST EXCITING DRUG
Call centres are typically responsible for a high percentage of safety report entry. However, the nature of the reporting process means it is hard to
Understanding patient safety is an essential element of Patient Support Programs. However, traditional safety reporting systems involve multi-step manual processes that often result in compliance
Safety reporting is not a core focus for field-based staff, therefore inputting of reports is often completed at a later time. This means report entry
A complete picture of drug safety cannot be created if only part of the available data is captured, however the current adverse event capture process
Through the input of industry leader members of the PV Insights Network, Qinecsa focuses on providing solutions to the safety challenges facing small pharmaceutical and
A top 10 pharma company faced challenges in standardizing safety surveillance across Pharma, Vaccine, and Consumer Health units, including consolidating signal teams, facilitating a divestment,
In her latest article for IPI, Qinecsa President, Humaira Qureshi discussed the practical challenges of integrating medical devices into pharmacovigilance portfolios, the obligations of device
2 Leman Street,
London, E1W 9US
United Kingdom
Company number: 13916274
